Asahi MG, Wallsh J, Onishi SM, et al. - Researchers conducted this randomized exploratory trial to compare monthly vs pro re nata (PRN) ranibizumab injections in the treatment of exudative macular degeneration (AMD) while evaluating the utility of microperimetry (MP) and multifocal electroretinography (mfERG) testing when monitoring response to treatment. They compared the effectiveness of monthly vs PRN dosing of ranibizumab (0.5 mg or 2.0 mg) for patients with exudative AMD over 12 months. Both PRN and monthly treatment of exudative AMD with ranibizumab enhance visual function as evaluated by best-corrected visual acuity and MP. In addition, macular thickening improved as shown by high-resolution optical coherence tomography findings. However, the reduced retinal function reported by mfERG indicates that, despite effective treatment, some loss of retinal function still exists. In future clinical trials, these visual function tests may be useful in evaluating retinal health and response to treatment.